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Treatment of alcohol-induced psychotic disorder (alcoholic hallucinosis) - a 
systematic review. 
Barkat Masood, Peter Lepping, Dmitry Romanov, Rob Poole.  
Abstract 
Background 
Alcohol-induced psychotic disorder (AIPD) is described by ICD-10 and DSM-5. It is 
a condition that is distinct from schizophrenia and has a close relationship with 
alcohol withdrawal states. There is sparse evidence to guide treatment of AIPD. 
Aims  
To evaluate the effectiveness of evidence based treatments for AIPD. 
Method 
A systematic review using PRISMA guidelines was conducted.  
Results 
 Of 6,205 abstracts found, fifteen studies and ten case reports met criteria and were 
examined. Larger studies examined the use of first generation antipsychotic drugs, 
reporting full or partial remission in most patients. Newer case reports report similar 
results using second generation antipsychotic drugs. Novel treatments, such as those 
acting on GABA receptors reported low numbers of patients in remission. Some large 
studies report the successful use of standard alcohol withdrawal treatments. 
Conclusion  
The findings of our systematic review are inconclusive. There was significant 





Randomised control trials of more carefully delineated samples would produce 
evidence of greater clinical utility, for example on differential effectiveness of 
antipsychotics and optimal length of standard alcohol withdrawal treatments.  AIPD 



























Excess alcohol consumption results in medical and social problems around the world. 
It accounts for 3% of global deaths (Rehm et al, 2009).  Neuropsychiatric 
consequences to alcohol dependence syndrome include delirium tremens, alcohol-
related brain damage, Korsakoff’s syndrome and alcoholic hallucinosis. The terms 
“alcoholic hallucinosis” and “alcohol-induced psychotic” disorder (AIPD) are often 
used interchangeably, although they may be better regarded as over-lapping 
categories. In this review we follow ICD-10 (WHO, 1992) in using the rubric AIPD to 
include both syndromes (ICD-10 code F10.5, corresponding to DSM-5 code 292.1).  
 
According to ICD-10 (WHO 2016 version), AIPD is a condition where mental and 
behavioural symptoms manifest within 2 weeks of alcohol use and must persist for 
more than 48 hours. Symptoms should not arise as part of alcohol intoxication or an 
alcohol withdrawal state. Clouding of consciousness should not be present to more 
than to a minor degree. An episode can persist for up to six months. A wide variety of 
symptoms can occur, including schizophreniform delusions, hallucinations, 
depression and mania. DSM-5 (APA, 2013) specifies that the substance should be 
capable of causing symptoms and that the condition should not be better explained by 
another psychotic disorder. 
 
There are a number of assertions made within the AIPD literature. In a Finnish study, 
AIPD was found to have a general population lifetime prevalence of 0.41%, or 4% for 
people with alcohol dependence syndrome. It was most common amongst men of 
working age (Perälä et al, 2010). AIPD is said to manifest immediately after the 





dependence syndrome (George & Chin, 1998; Perälä et al, 2010). Symptoms may 
develop during alcohol intoxication or withdrawal or soon thereafter. The diagnosis 
cannot be made until clear consciousness is restored. AIPD is said to usually resolve 
within 18 to 35 days with antipsychotic and/or benzodiazepine treatment (Vicente 
Muelas et al, 1990). A minority of patients may have persistent symptoms for six 
months or more (Benedetti, 1952; Bradley-Burton, 1958). AIPD may end through 
alcohol abstinence alone and return soon after reinstatement of drinking (Glass, 
1989b). The assertion that antipsychotic drugs are the treatment of choice (Jordaan & 
Emsley, 2014; Soyka, 1988) is not supported by published randomised controlled 
trials (RCTs). A number of factors affecting people with AIPD make it difficult to 
recruit and retain participants in RCTs (Perälä et al, 2010).  
 
There are few rigorous published studies of treatments for AIPD. This systematic 
review was conducted in order to evaluate the available evidence on treatment. 
 
Methods  
PRISMA Guidelines were used to carry out a systematic review. Medline, EMBASE, 
PsychINFO, Cochrane and CINAHL databases were searched for studies that had 
been published between 1st January 1900 and 18th August 2016. Subject search terms 
were: hallucinations / or alcoholism / or psychoses / or alcoholic psychoses / or 
chemically induced, drug therapy, prevention & control, rehabilitation, therapy / or 
alcohol intoxication / or delusions / or delirium / or dissociative disorders. (Search 
strategy available on request.)   
 





 had been published in any  language, 
 investigated alcohol with or without polysubstance misuse,  
 investigated  hallucinations,  
 investigated hallucinations attributed to alcohol and polysubstance misuse,  
 investigated hallucinations that persisted beyond  one week of alcohol/drug 
withdrawal state, 
 investigated any treatment of symptoms,  
 investigated any outcome measures,  
 investigated patients of any age,  
 were RCTs,  
 were case reports or series. 
 
 There were eight exclusion criteria during the screening phase: 
 papers that did not have abstracts (Criterion 1), 
 non-human studies (Criterion 2), 
 examined acute confusional states/delirium, symptoms that occurred during  
alcohol/drug withdrawal states of less than one week duration, delirium 
tremens, drug intoxication states and organic psychoses (Criterion 3),  
 did not examine hallucinations or psychoses (Criterion 4), 
 examined schizophrenia, bipolar disorder, mood disorder or delusional 
disorder (Criterion 5), 
 did not examine  alcohol related hallucinosis or examined hallucinations due 
to polysubstance misuse (Criterion 6), 
 single case studies  (Criterion 7) and 






The minimum standard for outcome measures was classification into no remission, 
partial remission or full remission.  
 
RESULTS 
7,347 articles were identified and 6,205 remained after duplicates were removed. 
Abstracts for the 6,205 articles were screened and the 8 exclusion criteria applied. 
Twenty-six full text articles were requested to assess eligibility. (See PRISMA flow 
chart Figure 1.) 
 
In December 2016, a search on the ClinicalTrials.gov (www.clinicaltrials.gov), the 
ISRCTN Registry (www.ISRCTN.com), the EU Clinical Trials 
(www.clinicaltrialsregister.eu) and the UK Clinical Trials Gateway 
(www.ukctg.nihr.ac.uk) websites did not find any completed or ongoing RCTs of 
treatment of AIPD.  
 
Fifteen studies (for details see Table 1) and ten case reports (Table 2) on the treatment 
of AIPD were included in the final analysis. A meta-analysis with funnel plot was not 
conducted because studies were few and too heterogeneous. 
 
Trial studies:  Four studies retrieved were double blind RCTs, of which one was a 
crossover study. One study included comparison with a group of participants with a 
diagnosis of paranoid schizophrenia. Ten studies were open label, non-comparative 






Five of the included studies examined cases of AIPD arising in the context of alcohol 
withdrawal (psychotic symptoms started during the withdrawal state but persisted 
after other withdrawal symptoms had resolved). The trials are summarised in Table 1. 
 
Table 1 about here 
 
 Types of treatment 
 
1.Antipsychotics: No trials examined the use of second-generation antipsychotics. Six 
trials examined the use of single or multiple first generation antipsychotics, including 
haloperidol, chlorpromazine, trifluoperazine, reserpine, thiotixene and levopromazine. 
 
Three trials examined the use of antipsychotics, benzodiazepines, vitamin B1 with 
treatment outcomes, but did not specify which antipsychotic drug was used.  
 
2. Anticonvulsants: Anticonvulsants were used in three trials (lamotrigine, sodium 
valproate and phenobarbitone). Hypnotics such as barbamyl and chloral hydrate were 
used in one trial.  
 
3. Others: Two trials examined other compounds that act on GABA receptors 
(piracetam and clorazepate).  
 
One trial examined the primary use of an unusual treatment (glycine). One trial 






Treatment results:  
There was marked heterogeneity of results, even with the same drug. For example, 
full remission rates for chlorpromazine varied from 0% to 68%, and partial remission 
rates from 0% to 32%. Better results with haloperidol included full remission rates of 
68% to 90%, and partial remission rates of 0% to 30%. However, there were few trials 
of antipsychotic monotherapy, so findings are hard to fully interpret.   
Heterogeneous outcomes were also evident in trials of non-antipsychotic treatments, 
apart from one trial of three patients treated with ECT, all of whom experienced full 
remission. 
 
Treatment duration ranged from 3 days to 546 days, but most trials were brief.  
Longer duration was not associated with more favourable outcomes. In three trials, 
duration was not stated.  
 
Participants were predominantly male, as noted by Szefal & Zaleski (1983), who 
studied women with AIPD.  Cohort sizes ranged from 3 to 100. Ten trials involved 
between 24 and 40 participants.  
 
Case reports  
The ten case report papers reported 13 separate patients who were exposed to 21 
different treatments or treatment combinations. All patients were treated with first- or 
second-generation antipsychotics. Three patients were treated with adjunctive 
benzodiazepines and vitamin B1.  
 






Treatments and outcomes are set out in Table 2. Outcomes were highly variable. Five 
patients experienced full remission with risperidone and two with olanzapine. No 
remission occurred in patients treated with chlorpromazine, perazine, flupenthixol, 
trifluoperazine or quetiapine. Of three treatment episodes with haloperidol, only one 
led to (partial) remission. There were two electroconvulsive therapy treatment 
episodes, both of which were associated with full remission. However, it should be 
noted that the most recent report of ECT for AIPD was published in 1956.  
 
Full remission was reported in one patient treated with transcranial direct current 
stimulation following failure of three different first generation or second generation 
antipsychotic drugs  
 
Discussion 
Previous reviews of AIPD have focussed on aetiology, symptoms, prognosis and the 
relationship with schizophrenia (Soyka, 1994; Jordaan & Emsley, 2013; Engelhard et 
al, 2015). This is the first systematic review to examine treatment of AIPD. We 
included part of the non-English language literature, papers written in Dutch, French, 
German, Polish, Russian and Spanish. All papers were translated by PL or DR who 
are fully fluent in the respective languages, with the exception of Polish and Spanish 








The findings of our systematic review are inconclusive. Studies generally had 
relatively low numbers of participants. There were few RCTs. Treatments were 
sometimes idiosyncratic, although these were usually supported by a rationale. For 
example, Aliyev and colleagues (Aliyev & Aliyev 2005,2008; Aliyev et al, 2011) 
justified their treatment with glycine, lamotrigine and sodium valproate by reference 
to Branchey et al (1985), who suggest that amino acid abnormalities affect cerebral 
serotonin and dopamine levels and thus cause hallucinations. Their results do not 
support the use of these treatments. They reported high partial remission rates in 
RCTs but the trials were brief (10 days) with no indication of longer-term outcomes. 
High doses of medication were used.  These may have caused sedative side effects, 
confounding findings of partial remission.  
 
Overall, larger studies tended to report at least partial remission on antipsychotic 
medications, whether in combination with other treatments or as monotherapy. Some 
case reports concerned treatment with second-generation antipsychotics. Insofar as it 
is possible to tell, these appear to be no better or worse than older drugs.  
 
Problems in studying treatments for AIPD 
 
The sparseness of the literature is surprising, as alcohol dependence syndrome is 
common and AIPD is a serious complication of the condition. However, there are 
several problems in studying treatments for AIPD: 
 
Firstly, it may be difficult to recruit and retain participants who are both alcohol 





difficult to achieve.  Participants are likely to live in difficult social situations due to 
alcohol excess (Ali & McBride, 1997). These factors make compliance and retention 
in rigorous trials difficult. 
 
Secondly, poor treatment outcomes in longer studies may lead to participants 




The literature on AIPD and alcoholic hallucinosis has been dominated by attempts to 
ascertain whether there is a single syndrome, distinct from schizophrenia and delirium 
tremens, or whether there are several alcohol-related psychotic syndromes, either 
discrete or overlapping. 
 
We found that all studies and case reports matched ICD-10 and DSM-5 criteria. All 
studies and case reports excluded clouding of consciousness as a key diagnostic 
criterion, which is congruous with DSM-5 and ICD-10 criteria. All case reports and 
studies described auditory hallucinations as a key feature in AIPD but some authors 
reported hallucinations in other modalities. Auditory hallucinations were second and 
third person, commentary, derogatory and command types. Delusions of persecution 
and of jealousy were reported in some participants. Boriskov (1977) described 
delusions of grandeur in AIPD, while Jordaan et al (2012) found no evidence of 
significant delusions of grandeur. Interestingly, a few studies reported 
schizophreniform thought disorder (George & Chin, 1998; Vicent-Muelas et al, 





during excess alcohol consumption or on alcohol withdrawal. No auditory 
hallucinations commenced during periods of extended alcohol abstinence.  
 
The diagnosis of AIPD appears to have been stable in all studies. No changes of 
diagnosis to schizophrenia were observed. However, some participants experienced 
alcohol withdrawal symptoms, there was a wide range of psychopathology in different 
participants, and the timing of onset of AIPD was not always reported.  
 
Attempts have been made to distinguish between AIPD and schizophrenia 
complicated (or precipitated) by alcohol misuse. In the 1950s, three large-scale 
studies followed patients with AIPD for 5 to 23 years in order to examine prognosis 
and diagnosis (Benedetti, 1952; Burton-Bradley, 1958; Victor & Hope, 1958). The 
conclusion was broadly similar: the majority of patients studied did not have 
schizophrenia. Cutting (1978) concluded from a study of 46 patients that AIPD could 
be regarded as an organic psychosis, and if there was any resemblance to 
schizophrenia this was due to an emphasis on Schneider’s first rank symptoms in 
earlier editions of ICD and DSM.  He suggested that people with AIPD do not show 
features of schizophrenia as propounded by Bleuler (1911) -such as blunting of affect, 
autism, thought disorder and ambivalence - and by Kraepelin (1913). 
 A two part review by Glass (1989) emphasised that schizophrenia and AIPD have 
different onsets, different symptoms and different outcomes. This view was shared by 
Soyka (1994), who had reported that patients with AIPD were more likely to have a 
family history of alcohol misuse than psychosis, and vice versa for patients with 





between AIPD and schizophrenia (Schukit & Winokur, 1971; Rimmer & Jacobsen, 





These did not add significantly to our understanding of treatment strategies for AIPD. 
We found only ten case reports (See Table 2). Treatment periods were usually around 
56 days duration (Chaudhary & Augustine, 1991; Soyka, 1997; De Millas & Haasen, 
2007; Bouritius et al, 2015; Goyal, 2016). Full or partial remissions occurred within a 
matter of days or not at all.  
 
Remission on treatment with first generation antipsychotics was common, but some 
reported success with subsequent use of second-generation antipsychotics, 
strengthening the suspicion of publication bias. Only one case report reported no 
treatment remission (Hytinnen, 1987). Case studies are well recognised to be 
potentially misleading, and we do not believe that any reliance should be placed upon 
them.  
 
Non-pharmacological treatment strategies 
 
In a very small number of cases, ECT and transcranial direct current stimulation 
appeared to be effective treatments (Gruenberg, 1940; Bourdon, 1952; Goyal, 2016). 






There is a widely held clinical dictum that alcoholic hallucinosis does not resolve 
without complete abstinence from alcohol and that relapse of drinking tends to cause 
a return of hallucinations soon thereafter.  Abstinence on its own was not an effective 
treatment for AIPD in one case report (De Millas & Haasen, 2007). Nonetheless, this 
is a safe treatment strategy, and it is surprising that there are no studies reported 
anywhere in the literature of alcohol withdrawal followed by complete abstinence 
with no drug treatment.  This is a major gap in the evidence base.  
 
Recommendations for future research 
 
There is a prima facie case that the rubric AIPD is too broad to allow clear findings 
for treatment of different sub-types to be evident. This is evident in both DSM-5 and 
ICD-10 criteria. There is no evidence base to fall back on underpinning a pragmatic 
sub-classification. Although it is reasonable to conduct rigorous trials of treatment for 
a broad range of psychotic symptoms, we suggest that it would be helpful if future 
trials attempted to identify participants with relatively homogenous symptoms. The 
key variables to take into account are: 
 
1. Did psychotic symptoms first arise during alcohol intoxication or, conversely, 
during acute alcohol withdrawal? 
2. Are symptoms predominately hallucinations, delusions, or both? 
3. Is symptom duration one month, more than one month or more than six 
months? 
4. Do symptoms persist during abstinence?  






Greater clarity and homogeneity would distinguish, for example, participants who 
meet criteria for both schizophreniform psychosis and alcohol dependence syndrome 
from participants displaying a core “alcohol hallucinosis” as described by Lishman 
(1998), with persistent vivid auditory hallucinations that arise with a quality of 
insight, but few or no other psychotic symptoms. 
 
 
 Clinical implications 
 
Our systematic review suggests that there is adequate evidence that some patients 
with AIPD show a favourable response to antipsychotic medication. There is nothing 
to indicate the superiority of any particular drug. Both first- and second-generation 
drugs appear to be effective. However, it seems highly likely that many patients show 
little or no response to antipsychotics and that persistence when they fail to produce 
remission (whether partial or full) cannot be justified. There is no evidence to guide 
the duration of treatment. First principles would dictate that this should be as brief as 
possible, given the wide range of side effects associated with these medications.   
 
As complete abstinence from alcohol, when it can be achieved, slows or stops other 
alcohol-related disease processes, there is good reason to strongly recommend it.  
There is sufficient weight of clinical opinion to caution patients that even controlled 






There is insufficient evidence for other treatments reviewed here to recommend their 
routine use in the treatment of AIPD  
 
Conclusion and limitations:  
 
Given the relative dearth of data we chose a wide timeframe for our search. However, 
earlier papers may have included patients who may have been excluded if modern 
diagnostic techniques had been available. Furthermore, standard treatments such as 
antipsychotics were not available for a proportion of the early studies. Much of the 
evidence for treatment of AIPD is weak and is only level IV evidence (Agency for 
Health Care Policy and Research, 1992). The lack of research on AIPD may be due to 
a belief that it is easy to treat (Jordaan & Emsley, 2014; Soyka, 1988). However, this 
is mistaken as hospital readmission rates are high (Soyka et al, 2013). There is little 
clarity on how best to treat patients with persistent symptoms. 
 
Heterogeneity is a problem in the studies found. We suggest that  
 
distinguishing between key variables of AIPD would help to understand  
 
the findings of future treatment trials. 
The evidence for the effectiveness of first- and second-generation antipsychotic drugs 
is based upon case reports and underpowered trials. Positive publication bias is likely. 
A funnel plot was not feasible due to the size and nature of the literature. There is 
supportive evidence to use this treatment, but better evidence is needed. Similar 
considerations affect studies using novel treatments such as GABA receptor 
compounds, but the lack of positive findings means that they cannot be recommended 
in the treatment of AIPD. Although some larger studies report the successful use of 





unexamined. There is an important gap in the literature on the management of patients 
whose symptoms fail to remit in response to antipsychotic medication. 
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N, age range Outcome: no remission, partial 













Case series* Electroconvulsive therapy 
wavelength 7.5 metres; 15 
minutes per treatment. Self 
structured scale of improvement 
or no improvement. 





Males 3; aged 
28 -40. 
Full remission: 3 (100%) * 
Bobrov 







Unknown 100 patients  No remission: 100 (100%) 
Morales-
Beda & de 
Haro de La 
Cruz (1968) 
Case series Neuroleptic free prior to 
treatment. 
Thiotixene 30 - 60mg /day. 


















phenobarbitone, barbital sodium, 
chloral hydrate also used .Doses 
unknown]. 
 
28-168 73 patients   Full remission: 50 (68%)  
Partial remission: 23 (32%)** 
Boriskov 
(1977) 




Antipsychotics, vitamin B1 (100- 
200mg) and Biyohinol/ 
Bioochinolum preparation 
(quinine bismuth iodide) up to 40-
50ml  




















Initial period -chlorpromazine or 
Trifluoperazine (dose equivalents 
chlorpromazine 400mg- 1200mg). 
Then Chlorpromazine or 
trifluoperazine (dose equivalents 
chlorpromazine 300-1,000mg).  
Self constructed outcome scale of 
full remission, partial remission 















Alcoholic hallucinosis:  
Full remission: 19 (63%), 
Partial remission: 7 (23%),    
No remission: 4(13%). 
Paranoid schizophrenia:  
Full remission: 4(13%),  
 Partial remission: 11 (37%),  
















Piracetam 9.0g/day and IV 
Diazepam up to 20mg/day.  
Brief Psychiatric Rating Scale. 
 
6 24 male patients 
(16 withdrawal 
states and 8 
alcohol 
hallucinosis)  
Total patients: partial response: 
21(100%).  21 completed, 3 in first 
placebo period withdrawn due 
neuroleptic use.  1 patient of initial 
piracetam group required IV diazepam. 
7 of placebo required IV diazepam. 
Alcohol hallucinosis: partial remission: 
8 (100%)***  
 
Vencovsky 






Case series† Clorazepate 200mg - 600mg/day 
(Intra muscularly or 
intravenously). Oral clorazepate 
used after parenteral treatment. 
Brief Psychiatric Rating Scale  
2-3 35 patients 
(21 delirium 
tremens and 14 
alcoholic 
hallucinosis). 
Alcoholic hallucinosis: Full remission: 
8 (57%). No remission: 6(43%) 
following parenteral treatment.† 
 Vicente-
Muelas , 
Rios Rial & 
Ochoa 
Mandago  
Case series Antipsychotics, benzodiazepines 
and vitamin B1 (No names or 
doses). 
Self constructed scale: full 
remission, partial remission, no 
18 - 35 25 (23 male and 
2 female) 
 
Full remission: 16 (64%), 
Partial remission: 6 (24%),  













Case series†† Diazepam 30-40mg/day. Vitamin 
B1 (1 ampoule/day) for 3 days, 
then 200mg/ day. Haloperidol 30-
40mg/day.  
Self constructed scale of full 




34 patients (32 
male and 2 
female)  
 
Full remission: 27 (85%),  
No remission: 5 (15%).†† 
32 eligible patients as 2 had delirium 







controlled trial.  
700mg sublingual glycine /day.  
5 point scale (1=absent, 2=slight, 
3=moderate, 4=significant, 
5=high),Wilcoxon Rank Sum test. 
7 40 male 
patients. 20 to 
drug and 20 to 
placebo. 
 
Sublingual glycine: partial remission: 
20 (100%) 
 














Starting dose of 1,000mg/day, 
increased to 3,000mg.  









Sodium valproate (19 completers):  
Partial remission: 14 (74%), 
No remission: 5 (26%). 
 
Placebo (20 completers): 
Partial remission: 5 (25%), 
No remission: 15 (75%). 







Positive And Negative Symptoms 
Scale, subscale for hallucinosis. 




Lamotrigine: partial remission: 20 
(100%) 








and vitamin B1. 
Unknown. 26 males ## Full remission: 24 (92%), 







 Table1.  Treatments and Outcomes in AIPD studies. 
 
*Assuming maximum of 2 treatments per 7 days. Although 2 or more treatments 
could occur in a day. 
 ** Unknown regimen. Original sample n=204. Mixture of delirium tremens, organic 
brain syndromes and AIPD. Relevant AIPD cases examined.  
*** Assuming that 3 participants withdrawn due to severity of withdrawal state and 
subsequently requiring antipsychotics. 
† 29 patients had full remission. It is assumed that all 21 patients with delirium 
tremens had full remission. 
††28 of 33 patients had complete remission. However, the adjustment of removing 1 
patient is because this patient had delirium tremens and is assumed to have had full 
remission.  
††† Original  mixed study (clearly defined cases of  delirium tremens, AIPD , 
Korsakov’s syndrome  and other  psychiatric disorder due to alcohol and 
psychostimulants) of n=125. 
 
 





comparative study)  
Haloperidol 5 mg /day. Extra 
pyramidal side effects treated 
with benzhexol (2-6mg/day) and 
lorazepam (max 4mg/day) for 
sedation/anxiety, infrequently 
used. Positive and Negative 
Symptoms Scale. 
42  20 patients (16 
male and 4 
female)  
Full remission: 18 (90%), partial 


























Table2. Treatment and outcomes in AIPD case reports.  
 
Authors  N     Age 
(years) 
















1 session. Full remission.  
 
55 M Electroconvulsive 
therapy. 
Unknown 1 session. Full remission. 
Hytinnen 
(1987) 




2 40 M Antipsychotics, 
vitamins,psychotherapy,  
supportive measures 
Unknown 56  Full remission* 
47 M Unknown 168 Full remission* 
Soyka 
(1997)** 
1 33 M Haloperidol decanoate   10  2190  No remission** 
Perazine  200 
Risperidone 6 56  Full remission** 




1 58 M Risperidone. 
Alcohol abstinence. 
2  5 Full remission. 




1    40 M Olanzapine  20 10 
 
Full remission***  
Citalopram. 40 





2 23 M  Risperidone, 
benzodiazepines and 
vitamin B1. 
4 42 Full remission† 
43 M 4 42 Full remission† 
Ogut, Suner 
& Citak 
1 58 M Diazepam   60 Unknown  Full  
remission 












1 38 M Quetiapine,  900  56 No remission†† 
Flupenthixol 18 56 No remission†† 
Haloperidol Unknown Unknown Partial remission †† 
Goyal 
(2016)††† 





56 No remission†††  








5 Full remission††† 
  
 
Please note: Outcomes dictate that an individual treatment episode occurred. Some 
patients received more than one treatment. Whenever more than one treatment is 
listed for a patient, the treatments listed were given consecutively. 
*Full remission after 56 and 168 days. Time of response suggested to be immediate. 
** Full remission occurred after a few days. 
*** Dose of risperidone not specified. Assumed to be maximum doses,  as per British 





†Four milligrams refers to dose of risperidone. Unknown type, dose and duration of 
benzodiazepine. Confirmed by email correspondence from B Masood to A Farcas. 
†† Doses and duration not specified for quetiapine and flupenthixol. Assumed to be 
adequate therapeutic trial at maximum doses, as per British National Formulary 70 
(2015). 












































































Records identified through 
database searching. 
(n =7347) 
 Duplicates removed. 
(n = 1142) 
Titles and abstracts screened. 
(n = 6205) 
Full-text articles assessed 
for eligibility. 
(n = 36) 
Studies included in 
qualitative synthesis: 
(n=15), in addition we 
identified 10 case reports  
Records excluded (n=6179): 
 
 Criterion 1 = 267 
 Criterion 2 = 1312 
 Criterion 3 = 1090 
 Criterion 4 = 2954 
 Criterion 5 = 266 
 Criterion 6 = 48 
 Criterion 7 = 105 
 Criterion 8 = 137 
Full-text articles excluded 
(n = 11 ): 
1) Bokun (1975) - Criterion 8 
2) Cade (1972) - Criterion 8 
3) Dvirskii (2000) - Criterion 8 
4) Hytinnen (1987) - Criterion 7 
5) Imamov (1986) - Criterion 8 
6) Levitin, Ezarielev & Levitin 
(1971) - Criterion 8 
7) Moefes (1970) - Criterion 8 
8) Sluchevskii, Tikomirov & 
Bakharov (1986) - Criterion 3 
9) Surawica (1980) - Criterion 7 
10) Wendland & Danzer (1987)- 
Criterion 8 
11) Szefal & Zaleski (1983) - 
Criterion 8 
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